<DOC>
	<DOC>NCT00116298</DOC>
	<brief_summary>The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations, each in combination with lamivudine (3TC) and efavirenz (EFV) in subjects who have completed Bristol-Myers Squibb (BMS) studies AI455-096 and AI455-099.</brief_summary>
	<brief_title>Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Completed d4T studies AI455096 or AI455099 Have demonstrated compliance with the study medication and treatment visits Provide written informed consent Agree to use a barrier method of birth control (such as condoms) during the study Have a negative pregnancy test within 72 hours prior to start of study medication Are pregnant or breastfeeding Need to take certain medications that have systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential Have active alcohol or substance abuse which may prevent compliance or increase risk of developing pancreatitis Have certain other conditions or prior treatments that might interfere with study continuation Need to take certain medications that should not be taken with EFV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Antivirals</keyword>
	<keyword>HIV</keyword>
</DOC>